Imaging Tests for Liver Disease in Children With Obesity
Studies imaging tests that may detect liver disease in children with obesity over time.
Plain-language title generated from the registry record
Registry title: HIBOC = Hepatic Imaging Biomarkers in Obese Children
Key facts
- Where
- Gothenburg, SwedenSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 9 and 14 years old?
Source: NCT06463223, who can take part
Where in Sweden
- Department of Radiology, Queen Silvias Children´s Hospital, Institution of Clinical SciencesGothenburg, SwedenNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sahlgrenska University Hospital
- Trial code
- NCT06463223
- Record updated
- 18 May 2026
- Original description
The goal of this prospective, diagnostic observational study is to learn about how imaging based markers for components of liver disease appear in children with obesity. It aims to determine whether the imaging markers (ultrasound and MRI) for liver disease can be tools to improve diagnostics for liver affection in children with obesity and to ascertain how the markers are related to multiple clinical measures, for example BMI and serology measure, and treatment effects over time.Read full original descriptionShow less
Imaging-based Biomarkers for Liver Disease in Children With Obesity-a Longitudinal Study
The goal of this prospective, diagnostic observational study is to learn about how imaging based markers for components of liver disease appear in children with obesity. It aims to determine whether the imaging markers (ultrasound and MRI) for liver disease can be tools to improve diagnostics for liver affection in children with obesity and to ascertain how the markers are related to multiple clinical measures, for example BMI and serology measure, and treatment effects over time.
Inclusion: Age 9 to 14 years; New referral/first visit or follow-up annual visit at each healthcare center (Child and adolescent oriented centers) included; BMI 30 or more; Obesity >1 year at inclusion.
Exclusion: Implants or other factors that prevent MRI (applies to the MRI cohort); Comorbidities that can affect the liver (e.g., medications or diseases with known liver impact); Difficulty understanding written/oral information; Claustrophobia (applies to the MRI cohort).